FEATURED ARTICLE

Immuno-PET Imaging to Assess Target Engagement: Experience from ⁸⁹Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors. C. Willemien Menke-van der Houven van Oordt et al. See page 902.

PET and P2X7 receptors: can a new PET probe reliably differentiate lung inflammation from tumor? Zhequan Fu et al. See page 930.

Novel PSMA-targeting agent: first-in-humans results on ¹⁸F-CTT1057 as an alternative to urea-based PET compounds in prostate cancer. Spencer Behr et al. See page 910.